A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer

Exclusion Criteria

• •Subject has received any prior radiation therapy or surgery for prostate cancer, except 1 course of palliative surgical therapy if it was used at least 4 weeks prior to day 1;
• •Previous use or are using a second-generation androgen receptor antagonist (enzalutamide, ARN-509, ODM-201), abiraterone, ketoconazole for prostate cancer, or other agents that will inhibit the production of androgens;
• •Have participated in an interventional clinical trial or been treated with the following drugs in the past 4 weeks prior to day 1: 5-alpha reductase inhibitors, estrogen, progestin, and herbal products known to decrease PSA levels ;
• •Evidence of brain metastasis or primary tumors;
• •Planned to initiate any other anti-tumor therapies during the study;
• •Unable to swallow, chronic diarrhea and intestinal obstruction, or the presence of a variety of other factors that affect drug use and absorption; Clinically significant cardiovascular diseases;
• •History of seizure or certain conditions that may predispose to seizure;
• •Severe concurrent disease and infection that, in the judgment of the investigator, would make the patient inappropriate for enrollment.